Completed PHASE1 INTERVENTIONAL NCT00378287

A Study to Monitor Intragastric pH in Patients Taking Rabeprazole vs. Patients Taking Pantoprazole

A Randomized, Controlled, Double-blind, Cross-over Study of the Effect of Oral Rabeprazole 20mg and Intravenous Pantoprazole 40mg on Intragastric pH in Patients

Sponsor: Janssen-Ortho Inc., Canada

Conditions GERD

Interventions rabeprazole sodium

Updated 5 times since 2017 Last updated: Dec 7, 2012 Started: Oct 31, 2005 Completion: Dec 31, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00378287, this PHASE1 trial focuses on GERD and remains completed. Sponsored by Janssen-Ortho Inc., Canada, it has been updated 5 times since 2005, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Oct 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Janssen-Ortho Inc., Canada

Data source: Janssen-Ortho Inc., Canada

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.